Joint British Association for Sexual Health and HIV and Royal College of Obstetricians and Gynaecologists national UK guideline for the management of herpes simplex virus (HSV) in pregnancy and the neonate (2024 update)
Restricted accessResearch articleFirst published online January, 2025
Joint British Association for Sexual Health and HIV and Royal College of Obstetricians and Gynaecologists national UK guideline for the management of herpes simplex virus (HSV) in pregnancy and the neonate (2024 update)
This updated national UK guideline offers recommendations on the management of genital herpes simplex virus (HSV) in mothers and pregnant people during pregnancy and within 4 weeks following birth. It includes recommendations for first episode and recurrent HSV, HSV in preterm pre-labour rupture of membranes and in co-infection with HSV and HIV. Recommendations around management of the neonate are made, on prevention of postnatal transmission, management of breastfeeding, and the management of clinically discordant couples. This guideline is aimed at healthcare professionals working in sexual health clinics, maternity units, and those working on postnatal wards and neonatal units in the UK. However, the principles of the recommendations should be adopted across all services, including community care.
CoreyLWaldA. Maternal and neonatal herpes simplex virus infections. N Engl J Med2009; 361(14): 1376–1385.
7.
WhitleyRArvinAProberC, et al.Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The national Institute of allergy and infectious diseases collaborative antiviral study group. N Engl J Med1991; 324(7): 450–454.
8.
WhitleyRJNahmiasAJSoongSJ, et al.Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics1980; 66(4): 495–501.
9.
TookeyPPeckhamCS. Neonatal herpes simplex virus infection in the British Isles. Paediatr Perinat Epidemiol1996; 10(4): 432–442.
10.
British Paediatric Surveillance Unit, Royal College of Paediatrics and Child Health, Royal College of Paediatrics and Child Health. BPSU 21st annual report 2006-2007, 2007. https://www.rcpch.ac.uk/work-we-do/bpsu/annual-reports.
11.
BatraDDaviesPManktelowBN, et al.The incidence and presentation of neonatal herpes in a single UK tertiary centre, 2006-2013. Arch Dis Child2014; 99(10): 916–921.
12.
LookerKJMagaretASMayMT, et al.First estimates of the global and regional incidence of neonatal herpes infection. Lancet Glob Health2017; 5(3): e300–e309.
13.
HemelaarSJALPoeranJSteegersEAP, et al.Neonatal herpes infections in The Netherlands in the period 2006-2011. J Matern Fetal Neonatal Med2015; 28(8): 905–909.
14.
PattonMEBernsteinKLiuG, et al.Seroprevalence of herpes simplex virus types 1 and 2 among pregnant women and sexually active, nonpregnant women in the United States. Clin Infect Dis2018; 67(10): 1535–1542.
15.
MatthiasJduBSSchillingerJA, et al.Estimating neonatal herpes simplex virus incidence and mortality using capture-recapture, Florida. Clin Infect Dis Off Publ Infect Dis Soc Am2021; 73(3): 506–512.
16.
DondaKSharmaMAmponsahJK, et al.Trends in the incidence, mortality, and cost of neonatal herpes simplex virus hospitalizations in the United States from 2003 to 2014. J Perinatol2019; 39(5): 697–707.
17.
van OeffelenLBiekramMPoeranJ, et al.Update on neonatal herpes simplex epidemiology in The Netherlands: a health problem of increasing concern?Pediatr Infect Dis J2018; 37(8): 806–813.
18.
MahantSHallMSchondelmeyerAC, et al.Neonatal herpes simplex virus infection among medicaid-enrolled children: 2009-2015. Pediatrics2019; 143(4): e20183233.
19.
PuhakkaLSarvikiviELappalainenM, et al.Decrease in seroprevalence for herpesviruses among pregnant women in Finland: cross-sectional study of three time points 1992, 2002 and 2012. Inf Disp2016; 48(5): 406–410.
20.
DelaneySGardellaCSaracinoM, et al.Seroprevalence of herpes simplex virus type 1 and 2 among pregnant women, 1989-2010. JAMA2014; 312(7): 746–748.
LangenbergAGCoreyLAshleyRL, et al.A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med1999; 341(19): 1432–1438.
24.
HensleighPAAndrewsWWBrownZ, et al.Genital herpes during pregnancy: inability to distinguish primary and recurrent infections clinically. Obstet Gynecol1997; 89(6): 891–895.
25.
BrownZ. Preventing herpes simplex virus transmission to the neonate. Herpesviridae2004; 11(Suppl 3): 175A–186A.
26.
BrownZAWaldAMorrowRA, et al.Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA, J Am Med Assoc2003; 289(2): 203–209.
27.
DiguetAPatrierSEurinD, et al.Prenatal diagnosis of an exceptional intrauterine herpes simplex type 1 infection. Prenat Diagn2006; 26(2): 154–157.
28.
VasileiadisGTRoukemaHWRomanoW, et al.Intrauterine herpes simplex infection. Am J Perinatol2003; 20(2): 55–58.
AshleyRLDalessioJBurchettS, et al.Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. J Clin Invest1992; 90(2): 511–514.
SheffieldJSHollierLMHillJB, et al.Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol2003; 102(6): 1396–1403.
33.
WattsDHBrownZAMoneyD, et al.A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol2003; 188(3): 836–843.
34.
ScottLLHollierLMMcIntireD, et al.Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol2002; 10(2): 71–77.
35.
BrocklehurstPKinghornGCarneyO, et al.A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol1998; 105(3): 275–280.
36.
ScottLLSanchezPJJacksonGL, et al.Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol1996; 87(1): 69–73.
37.
BraigSLutonDSibonyO, et al.Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. Eur J Obstet Gynecol Reprod Biol2001; 96(1): 55–58.
38.
HollierLMWendelGD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev2008; 1: CD004946.
39.
SheffieldJSHillJBHollierLM, et al.Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol2006; 108(1): 141–147.
PinnintiSGAngaraRFejaKN, et al.Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. J Pediatr2012; 161(1): 134–138.
42.
NakubulwaSKayeDKBwangaF, et al.Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial. Reprod Health2017; 14(1): 31.
PasternakBHviidA. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA, J Am Med Assoc2010; 304(8): 859–866.
45.
YoungEJChafizadehEOliveiraVL, et al.Disseminated herpesvirus infection during pregnancy. Clin Infect Dis1996; 22(1): 51–58.
46.
HittiJWattsDHBurchettSK, et al.Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Am J Obstet Gynecol1997; 177(2): 450–454.
47.
ChenKTSegúMLumeyLH, et al.Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet Gynecol2005; 106(6): 1341–1348.
48.
HengMCHengSYAllenSG. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet1994; 343(8892): 255–258.
ShiTLHuangLJXiongYQ, et al.The risk of herpes simplex virus and human cytomegalovirus infection during pregnancy upon adverse pregnancy outcomes: a meta-analysis. J Clin Virol2018; 104: 48–55.
52.
SyridouGSpanakisNKonstantinidouA, et al.Detection of cytomegalovirus, parvovirus B19 and herpes simplex viruses in cases of intrauterine fetal death: association with pathological findings. J Med Virol2008; 80(10): 1776–1782.
53.
ZhouYBianGZhouQ, et al.Detection of cytomegalovirus, human parvovirus B19, and herpes simplex virus-1/2 in women with first-trimester spontaneous abortions. J Med Virol2015; 87(10): 1749–1753.
54.
BrownZABenedettiJSelkeS, et al.Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor. Obstet Gynecol1996; 87(4): 483–488.
55.
EskildAJeanssonSStray-PedersenB, et al.Herpes simplex virus type-2 infection in pregnancy: no risk of fetal death: results from a nested case-control study within 35,940 women. BJOG An Int J Obstet Gynaecol2002; 109(9): 1030–1035.
56.
HowleyMMFeldkampMLPapadopoulosEA, et al.Maternal genitourinary infections and risk of birth defects in the national birth defects prevention study. Birth Defects Res2018; 110(19): 1443–1454.
57.
VoektCARinderknechtTHirschHH, et al.Ultrasound indications for maternal STORCH testing in pregnancy. Swiss Med Wkly2017; 147: w14534.
58.
AcsNBánhidyFPuhóE, et al.No association between maternal recurrent genital herpes in pregnancy and higher risk for congenital abnormalities. Acta Obstet Gynecol Scand2008; 87(3): 292–299.
59.
MariaggiAABoujenahJL’HonneurAS, et al.Genital zoster in near term pregnancy: case report and need of management guidelines. J Gynecol Obstet Hum Reprod2020; 49(2): 101675.
60.
Magdaleno-TapialJHernández-BelPOrtiz-SalvadorJM, et al.Genital herpes zoster: a rare location that can mimic genital herpes. Sex Transm Dis2022; 49(1): e34–e36.
WongJLangfordAHowardDL. Nonsexually transmitted genital ulcer secondary to hand, foot, and mouth disease. Obstet Gynecol2019; 133(6): 1269–1273.
63.
HoweBBastaMFosterK, et al.Primary syphilis in pregnancy mistaken for genital herpes: a preventable cause of congenital syphilis. Eur J Obstet Gynecol Reprod Biol2017; 219: 133.
LiDKRaebelMACheethamTC, et al.Genital herpes and its treatment in relation to preterm delivery. Am J Epidemiol2014; 180(11): 1109–1117.
66.
AndrewsWWKimberlinDFWhitleyR, et al.Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol2006; 194(3): 774–781.
67.
StoneKMReiff-EldridgeRWhiteAD, et al.Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. Birt Defects Res A Clin Mol Teratol2004; 70(4): 201–207.
68.
RatanajamitCVinther SkriverMJepsenP, et al.Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study. Scand J Infect Dis2003; 35(4): 255–259.
69.
FrenkelLMBrownZABrysonYJ, et al.Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol1991; 164(2): 569–576.
70.
KimberlinDFWellerSWhitleyRJ, et al.Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol1998; 179(4): 846–851.
71.
BrownZAVontverLABenedettiJ, et al.Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med1987; 317(20): 1246–1251.
72.
ProberCGSullenderWMYasukawaLL, et al.Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med1987; 316(5): 240–244.
73.
BrownZABenedettiJAshleyR, et al.Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med1991; 324(18): 1247–1252.
74.
WaldAEricssonMKrantzE, et al.Oral shedding of herpes simplex virus type 2. Sex Transm Infect2004; 80(4): 272–276.
75.
AshleyRL. Sorting out the new HSV type specific antibody tests. Sex Transm Infect2001; 77(4): 232–237.
76.
Ashley-MorrowRKrantzEWaldA. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis2003; 30(4): 310–314.
77.
RekabdarETunbäckPLiljeqvistJA, et al.Dichotomy of glycoprotein g gene in herpes simplex virus type 1 isolates. J Clin Microbiol2002; 40(9): 3245–3251.
78.
LiljeqvistJASvennerholmBBergströmT. Herpes simplex virus type 2 glycoprotein G-negative clinical isolates are generated by single frameshift mutations. J Virol1999; 73(12): 9796–9802.
79.
DaikokuTHoribaKKawanaT, et al.Novel deletion in glycoprotein G forms a cluster and causes epidemiologic spread of herpes simplex virus type 2 infection. J Med Virol2013; 85(10): 1818–1828.
80.
Eis-HübingerAMDäumerMMatzB, et al.Evaluation of three glycoprotein G2-based enzyme immunoassays for detection of antibodies to herpes simplex virus type 2 in human sera. J Clin Microbiol1999; 37(5): 1242–1246.
81.
PrinceHEBattermanHJMarloweEM. Characterization of serum samples with discordant results in 2 herpes simplex virus type 2 IgG assays. Sex Transm Dis2022; 49(5): 353–359.
82.
MorrowRFriedrichD. Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. Clin Microbiol Infect2006; 12(5): 463–469.
83.
KimIDChangHSHwangKJ. Herpes simplex virus 2 infection rate and necessity of screening during pregnancy: a clinical and seroepidemiologic study. Yonsei Med J2012; 53(2): 401–407.
84.
NHS England. Saving babies’ lives version three. 2023.
85.
SénatMVAnselemOPiconeO, et al.Prevention and management of genital herpes simplex infection during pregnancy and delivery: guidelines from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol2018; 224: 93–101.
86.
BrownELMorrowRKrantzEM, et al.Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Am J Obstet Gynecol2006; 195(1): 115–120.
87.
NahmiasAJJoseyWENaibZM, et al.Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol1971; 110(6): 825–837.
National Institute for Health and Care Excellence. Intrapartum care for healthy women and babies: clinical guideline, 2014. https://www.nice.org.uk/guidance/cg190.
MajorCATowersCVLewisDF, et al.Expectant management of preterm premature rupture of membranes complicated by active recurrent genital herpes. Am J Obstet Gynecol2003; 188(6): 1551–1554.
92.
UtleyKBrombergerPWagnerL, et al.Management of primary herpes in pregnancy complicated by ruptured membranes and extreme prematurity: case report. Obstet Gynecol1987; 69(3 Pt 2): 471–473.
93.
DietrichYMNapolitanoPG. Acyclovir treatment of primary herpes in pregnancy complicated by second trimester preterm premature rupture of membranes with term delivery: case report. Am J Perinatol2002; 19(5): 235–238.
94.
ThomsonAJRoyal College of Obstetricians and Gynaecologists. Care of women presenting with suspected preterm prelabour rupture of membranes from 24+0 Weeks of gestation: green-top guideline No. 73. BJOG An Int J Obstet Gynaecol2019; 126(9): e152–e166.
95.
StockSJThomsonAJPapworthSRoyal College of Obstetricians and Gynaecologists. Antenatal corticosteroids to reduce neonatal morbidity and mortality: green-top Guideline No. 74. BJOG An Int J Obstet Gynaecol2022; 129(8): e35–e60.
96.
EhsanipoorRMMajorCA. Herpes simplex and HIV infections and preterm PROM. Clin Obstet Gynecol2011; 54(2): 330–336.
97.
SivarajahVVenusKYudinMH, et al.Does maternal HSV-2 coinfection increase mother-to-child transmission of HIV? A systematic review. Sex Transm Infect2017; 93(8): 535–542.
98.
Aebi-PoppKBaileyHMalyutaR, et al.High prevalence of herpes simplex virus (HSV)- type 2 co-infection among HIV-positive women in Ukraine, but no increased HIV mother-to-child transmission risk. BMC Pregnancy Childbirth2016; 16: 94.
99.
DrakeALJohn-StewartGCWaldA, et al.Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol2007; 109(2 Pt 1): 403–409.
100.
WarszawskiJTubianaRLe ChenadecJ, et al.Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS Lond Engl2008; 22(2): 289–299.
101.
BollenLJWhiteheadSJMockPA, et al.Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission?AIDS Lond Engl2008; 22(10): 1169–1176.
102.
OuedraogoANagotNVergneL, et al.Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS Lond Engl2006; 20(18): 2305–2313.
103.
PattersonJHittiJSelkeS, et al.Genital HSV detection among HIV-1-infected pregnant women in labor. Infect Dis Obstet Gynecol2011; 2011: 157680.
104.
TosswillJ. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update). London: British HIV Association, p. 117.
105.
MelvinAJMohanKMSchifferJT, et al.Plasma and cerebrospinal fluid herpes simplex virus levels at diagnosis and outcome of neonatal infection. J Pediatr2015; 166(4): 827–833.
106.
NiewieskS. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol2014; 5: 446.
TaddioAKleinJKorenG. Acyclovir excretion in human breast milk. Ann Pharmacother1994; 28(5): 585–587.
112.
SheffieldJSFishDNHollierLM, et al.Acyclovir concentrations in human breast milk after valaciclovir administration. Am J Obstet Gynecol2002; 186(1): 100–102.
113.
DrakeALRoxbyACKiarieJ, et al.Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial. PLoS One2012; 7(4): e34635.
114.
WhitleyRJ. The use of antiviral drugs during the neonatal period. Clin Perinatol2012; 39(1): 69–81.
115.
National Institute for Health and Care Excellence. British national formulary for children, 2023. https://bnfc.nice.org.uk/.
116.
National Institute for Health and Care Excellence. British national formulary, 2023. https://bnf.nice.org.uk/.
117.
KotroniasDKapranosN. Detection of herpes simplex virus DNA in maternal breast milk by in situ hybridization with tyramide signal amplification. In Vivo1999; 13(6): 463–466.
118.
Sullivan-BolyaiJZFifeKHJacobsRF, et al.Disseminated neonatal herpes simplex virus type 1 from a maternal breast lesion. Pediatrics1983; 71(3): 455–457.
119.
ParraJCneudeFHuinN, et al.Mammary herpes: a little known mode of neonatal herpes contamination. J Perinatol2013; 33(9): 736–737.
120.
FieldSS. Fatal neonatal herpes simplex infection likely from unrecognized breast lesions. J Hum Lactation2016; 32(1): 86–88.
121.
KoelleDMBenedettiJLangenbergA, et al.Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med1992; 116(6): 433–437.
WaldALangenbergAGMKrantzE, et al.The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med2005; 143(10): 707–713.
124.
MartinETKrantzEGottliebSL, et al.A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med2009; 169(13): 1233–1240.
125.
WaldALangenbergAGLinkK, et al.Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA2001; 285(24): 3100–3106.
126.
MagaretASMujugiraAHughesJP, et al.Effect of condom use on per-act HSV-2 transmission risk in HIV-1, HSV-2-discordant couples. Clin Infect Dis2016; 62(4): 456–461.
127.
WaldASelkeSWarrenT, et al.Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis2006; 33(9): 529–533.
128.
GuptaRWaldAKrantzE, et al.Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis2004; 190(8): 1374–1381.
129.
CoreyLWaldAPatelR, et al.Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med2004; 350(1): 11–20.
130.
WaldAZehJBarnumG, et al.Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med1996; 124(1 Pt 1): 8–15.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
